Sage Therapeutic Stock Today
| SAGE Stock | USD 8.06 0.20 2.54% |
PerformanceGood
| Odds Of DistressLow
|
Sage Therapeutic is trading at 8.06 as of the 19th of March 2025, a 2.54 percent increase since the beginning of the trading day. The stock's lowest day price was 7.84. Sage Therapeutic has only a 6 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of July 2014 | Category Healthcare | Classification Health Care |
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Sage Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 61.48 M outstanding shares of which 4.41 M shares are at this time shorted by private and institutional investors with about 2.45 trading days to cover. More on Sage Therapeutic
Moving together with Sage Stock
Moving against Sage Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Sage Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Barry Greene | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Jakarta Stock Exchange, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSage Therapeutic can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sage Therapeutic's financial leverage. It provides some insight into what part of Sage Therapeutic's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sage Therapeutic (SAGE) is traded on NASDAQ Exchange in USA. It is located in 55 Cambridge Parkway, Cambridge, MA, United States, 02142 and employs 353 people. Sage Therapeutic is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 493.38 M. Sage Therapeutic conducts business under Biotechnology sector and is part of Health Care industry. The entity has 61.48 M outstanding shares of which 4.41 M shares are at this time shorted by private and institutional investors with about 2.45 trading days to cover.
Sage Therapeutic currently holds about 1.51 B in cash with (267.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.47, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Sage Therapeutic Probability Of Bankruptcy
Ownership AllocationSage Therapeutic shows a total of 61.48 Million outstanding shares. The majority of Sage Therapeutic outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Sage Therapeutic to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Sage Therapeutic. Please pay attention to any change in the institutional holdings of Sage Therapeutic as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sage Ownership Details
Sage Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 1.1 M | |
| Federated Hermes Inc | 2024-12-31 | 1.1 M | |
| D. E. Shaw & Co Lp | 2024-12-31 | 720.1 K | |
| 683 Capital Management Llc | 2024-12-31 | 630 K | |
| Jefferies Financial Group Inc | 2024-12-31 | 599 K | |
| Aqr Capital Management Llc | 2024-12-31 | 560.4 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 542.2 K | |
| Northern Trust Corp | 2024-12-31 | 524.4 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 485.4 K | |
| Blackrock Inc | 2024-12-31 | 4.9 M | |
| Vanguard Group Inc | 2024-12-31 | 4.8 M |
Sage Therapeutic Historical Income Statement
Sage Stock Against Markets
Sage Therapeutic Corporate Management
| Maren Killackey | Senior Relation | Profile | |
| Jim Doherty | Chief Officer | Profile | |
| Aaron MD | Medical Development | Profile | |
| Christopher Benecchi | Chief Officer | Profile | |
| Laura MD | Chief Officer | Profile | |
| Heinrich Schlieker | Senior Operations | Profile | |
| Albert Robichaud | Chief Scientific Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.59) | Revenue Per Share | Quarterly Revenue Growth (0.84) | Return On Assets | Return On Equity |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.